Macquarie Group’s Actinium Pharmaceuticals ATNM Stock Holding History

Macquarie Group’s Portfolio ATNM Stock Details ATNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-423	Closed	-$8K	–	2176
2017 Q4	$8K	Buy	+423	New	+$8.51K	﹤0.01%	2299

Other funds holding ATNM

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

DAM

DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Macquarie Group's ATNM Position: Q1 2018 in Review

Macquarie Group sold out of Actinium Pharmaceuticals (ATNM) in Q1 2018, closing a stake of 423 shares — an estimated $8K sold.

Macquarie Group first reported a position in ATNM in Q4 2017 and held it in 1 quarter. The position peaked at $8K in Q4 2017. 36 funds tracked by Wall St. Rank hold ATNM as of Q1 2018.

Macquarie Group reported no remaining Actinium Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
Macquarie Group sold 423 Actinium Pharmaceuticals shares in Q1 2018, an estimated $8K.
Macquarie Group first reported a position in Actinium Pharmaceuticals in Q4 2017 and held it in 1 quarter.
Macquarie Group's Actinium Pharmaceuticals position peaked at $8K in Q4 2017.
36 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2018.

Based on Macquarie Group's 13F filing for Q1 2018, filed 11 May 2018.